Novo Nordisk A/S
(NYSE:NVO)
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
top performing NVO trades
Recent Trades
Largest Trades
Top Performing
Largest Traders
Most Active Traders
Recent Trades
View the most recent Novo Nordisk trades made by congress members.
![]() Tommy TubervilleSenate (R-AL) | $15K - $50K | stock | Sale | Feb 15, 2024 | Jan 19, 2024 | Senate |
![]() Daniel GoldmanHouse (D-NY) | $100K - $250K | stock | Sale | Aug 13, 2023 | Jul 12, 2023 | House |
![]() Daniel GoldmanHouse (D-NY) | $250K - $500K | stock | Sale | Aug 13, 2023 | Jul 10, 2023 | House |
![]() Katherine ClarkHouse (D-MA) | $1K - $15K | stock | Sale | Oct 14, 2021 | Sep 16, 2021 | House |